{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:57:50Z","timestamp":1792886270943,"version":"4.5.0"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Up to the beginning of 2018, a total of eight cases describing rare but clinically important drug interactions between rosuvastatin and ticagrelor which resulted in rhabdomyolysis have been noted in the Global World Health Organization (<jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>) adverse drug reaction (<jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>) database (VigiBase) as well as in available literature. There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin dose, drug\u2013drug interactions (<jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>) on metabolic enzymes (<jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>s and <jats:styled-content style=\"fixed-case\">UGT<\/jats:styled-content>s) and drug transporter levels (<jats:styled-content style=\"fixed-case\">ABCB<\/jats:styled-content>1, <jats:styled-content style=\"fixed-case\">ABCG<\/jats:styled-content>2, <jats:styled-content style=\"fixed-case\">OATP<\/jats:styled-content>1B1) and pharmacogenetic predisposition. We reviewed all available cases plus the case of an 87\u2010year\u2010old female Croatian\/Caucasian patient who developed rhabdomyolysis following concomitant treatment with rosuvastatin and ticagrelor. The results of the pharmacogenetic analysis indicated that the patient was a carrier of inactivating alleles <jats:italic><jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C9*1\/*3, <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A4*1\/*22, <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A5*3\/*3, <\/jats:italic><jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2D6<jats:italic>*1\/*4, <jats:styled-content style=\"fixed-case\">UGT<\/jats:styled-content>1A1*28\/*28, <jats:styled-content style=\"fixed-case\">UGT<\/jats:styled-content>2B7<\/jats:italic> \u2010161C\/T, <jats:italic><jats:styled-content style=\"fixed-case\">ABCB<\/jats:styled-content>1 3435C\/T and <jats:styled-content style=\"fixed-case\">ABCB<\/jats:styled-content>1 1237C\/T<\/jats:italic> which could have added to the interactions not only between ticagrelor and rosuvastatin but also other concomitantly prescribed medicines, such as amiodarone and proton pump inhibitors. In this case report, the possible multifactorial causes for rhabdomyolysis following concomitant use of rosuvastatin and ticagrelor such as old age, polypharmacy, renal impairment, along with pharmacogenetics will be discussed.<\/jats:p>","DOI":"10.1111\/bcpt.13035","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T22:49:35Z","timestamp":1525733375000},"page":"509-518","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Rosuvastatin\u2010Induced Rhabdomyolysis \u2013 Possible Role of Ticagrelor and Patients\u2019 Pharmacogenetic Profile"],"prefix":"10.1111","volume":"123","author":[{"given":"Majda","family":"Vrki\u0107 Kirhmajer","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases University of Zagreb School of Medicine University Hospital Centre Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Macoli\u0107 \u0160arini\u0107","sequence":"additional","affiliation":[{"name":"Safety and Vigilance WHO Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livija","family":"\u0160imi\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics University Hospital Centre Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Ladi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Bjelovar General Hospital Bjelovar Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kre\u0161imir","family":"Putarek","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases University Hospital Centre Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Banfi\u0107","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases University of Zagreb School of Medicine University Hospital Centre Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Bo\u017eina","sequence":"additional","affiliation":[{"name":"Department of Pharmacology University of Zagreb School of Medicine University Hospital Centre Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1661-6"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1369-4"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.41"},{"key":"e_1_2_10_7_1","first-page":"129","article-title":"ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421C>A are determinants of inter\u2010subject variability in rosuvastatin pharmacokinetics","volume":"68","author":"Zhou Q","year":"2013","journal-title":"Pharmazie"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.047647"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2013.03.019"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.197"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002857"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"e_1_2_10_14_1","first-page":"320","article-title":"Rhabdomyolysis precipitated by possible interaction of ticagrelor with high\u2010dose atorvastatin","volume":"2015","author":"Kido K","year":"2003","journal-title":"J Am Assoc"},{"key":"e_1_2_10_15_1","unstructured":"Crestor prescribing information(revised: 8\/2017) \u00a92018 AstraZeneca.https:\/\/www.azpicentral.com\/crestor\/crestor.pdf#page=1(last accessed on 5 January 2018)."},{"key":"e_1_2_10_16_1","unstructured":"European Medicines Agency: Brilique\u2010EMEA\/H\/C\/001241\u2010IA\/0036\/G \u2010 Brilique EPAR: Product information 18\/05\/2017. \u00a91995\u20102018 European Medicines Agency.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001241\/WC500100494.pdf(last accessed on 5 January 2018)."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00134.x"},{"key":"e_1_2_10_18_1","volume-title":"Stockley's Drug Interactions","author":"Baxter K","year":"2018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065623"},{"key":"e_1_2_10_20_1","unstructured":"MillerML.Clinical manifestations and diagnosis of rhabdomyolysis(updated Feb 08 2018). In: UpToDate Taegoff IN Shefner JM (Eds) \u00a9 2018 UpToDate Inc.https:\/\/www.uptodate.com(last accessed on 10 February 2018)."},{"key":"e_1_2_10_21_1","first-page":"136","article-title":"Ticagrelor\u2010induced renal failure leading to statin\u2010induced rhabdomyolysis","volume":"73","author":"Vuren AJ","year":"2015","journal-title":"Neth J Med"},{"key":"e_1_2_10_22_1","first-page":"e1633","article-title":"A unique case of drug interaction between ticagrelor and statin leading to acute renal failure","volume":"9","author":"Samuel G","year":"2017","journal-title":"Cureus"},{"key":"e_1_2_10_23_1","first-page":"1004","article-title":"A case of acute renal failure and rhabdomyolysis associated with the concomitant use of Ticagrelor, Rosuvastatin and Losartan","volume":"2","author":"New J","year":"2017","journal-title":"JMS Intern Med"},{"key":"e_1_2_10_24_1","unstructured":"Macolic SarinicV.Interaction between rosuvastatin and ticagrelor resulting in rhabdomyolysis: Uppsala Monitoring Centre; Signal April 2017.http:\/\/canhgiacduoc.org.vn\/SiteData\/3\/UserFiles\/SIGNAL%202017-2%20Final.pdf(last accessed on 6 January 2018)."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584380-000000000-00000"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-013-0028-5"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.11.003"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22063"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.031"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1477"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1543-3"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv116"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00474"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump\u2010inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Xq L","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100098"},{"key":"e_1_2_10_37_1","first-page":"66","article-title":"The role of metabolites in predicting drug\u2010drug interactions: focus on irreversible cytochrome P450 inhibition","volume":"13","author":"VandenBrink BM","year":"2010","journal-title":"Curr Opin Drug Discov Devel"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.13035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T10:04:09Z","timestamp":1694945049000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/bcpt.13035"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13035","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,29]]},"assertion":[{"value":"2018-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}